Observational analysis highlights the role of risperidone in situ microparticles in improving adherence and symptom control in schizophrenia patients.
Introduction A key challenge in managing schizophrenia is ensuring adequate adherence to antipsychotic treatment. Long-acting injectable (LAI) antipsychotics play a crucial role in improving adherence, yet certain clinical needs remain unmet, including a rapid symptom control and satisfactory efficacy/tolerability balance.
No takes yet. Share an insight, caveat, or question.
Filippis et al. (2025) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: